Lindland, Elisabeth S.
Solheim, Anne Marit
Dareez, Muhammad Nazeer
Eikeland, Randi
Ljøstad, Unn
Mygland, Åse
Reiso, Harald
Lorentzen, Åslaug R.
Harbo, Hanne F.
Beyer, Mona K.
Funding for this research was provided by:
Helse Sør-Øst RHF (2015113, 2020103, 2015113, 2013089)
University of Oslo
Article History
Received: 10 February 2022
Accepted: 8 April 2022
First Online: 24 May 2022
Declarations
: All procedures involving human participants in the study were in accordance with the ethical standards of the regional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Regional ethics committee (South-Eastern Norway Health Authority) and Institutional data protection services approved of the study. Participants gave written informed consent.
: The authors of this manuscript declare relationships with the following companies: Mona K. Beyer received minor grants or speaker’s fees from Biogen Idec, Merck, and Novartis. Hanne F. Harbo received minor grants or speaker’s fees from Biogen, Sanofi Genzyme, Teva, and Merck. Åslaug R. Lorentzen received minor grant from Sanofi. The other authors do not report any disclosures.